NervGen Pharma’s NVG-291 Delivers Breakthrough Results in Chronic Spinal Cord Injury Treatment: Clinical Trial Success and FDA Approval Pathways
NervGen Pharma's NVG-291 therapy shows breakthrough results in restoring function for chronic…
CRISPR Breakthrough: First Successful Gene Editing Cure for Rare Muscle Disorder in Phase 2 Human Trials
Boston's GenEdit Therapeutics announces the first CRISPR cure for rare muscle disorder…
